Meta‐analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. BJS 2018; 105: 1098-1106.
Published: 4th July 2018
Authors: C. A. Fleming, H. M. Heneghan, D. O'Brien, D. P. McCartan, E. W. McDermott, R. S. Prichard et al.
Optimal management of the endometrium in patients with oestrogen receptor‐positive breast cancer taking extended tamoxifen therapy (for 10 years) remains uncertain. A meta‐analysis was performed to determine the cumulative risk ratio (RR) for endometrial malignancy following extended compared with standard tamoxifen treatment. A systematic review was undertaken to identify whether routine endometrial surveillance in patients receiving tamoxifen is associated with earlier detection and reduced incidence of endometrial malignancy.
Two independent searches were undertaken in the Cochrane Library, PubMed and MEDLINE. A meta‐analysis was performed of RCTs reporting on endometrial malignancy risk in extended tamoxifen therapy. A systematic review included prospective studies investigating the benefit of endometrial surveillance during tamoxifen therapy.
Four RCTs reported on endometrial risk in extended tamoxifen therapy. The cumulative risk of endometrial malignancy increased twofold from 1·5 to 3·2 per cent with extended therapy compared with the standard 5 years of tamoxifen (RR 2·29, 95 per cent c.i. 1·60 to 3·28; P < 0·001). Four studies analysed the value of endometrial screening in 5‐year cohorts. Endometrial cancer rates of up to 2 per cent were reported, which is higher than rates in the large extended tamoxifen trials.
Extended adjuvant tamoxifen is associated with an increase in endometrial cancer. No clear benefit has been shown for routine endometrial surveillance in asymptomatic patients on tamoxifen therapy.Full text
You may also be interested in
Meta‐analysis of the diagnostic accuracy of ultrasound‐guided fine‐needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis.
Authors: I. Balasubramanian, C. A. Fleming, M. A. Corrigan, H. P. Redmond, M. J. Kerin, A. J. Lowery et al.
Notes: CNB better
Breast‐conserving surgery followed by whole‐breast irradiation offers survival benefits over mastectomy without irradiation.
Authors: J. de Boniface, J. Frisell, L. Bergkvist, Y. Andersson
Notes: RT to lower axilla key?
Is axillary ultrasound imaging necessary for all patients with breast cancer?. BJS 2018; 105: 930-932.
Authors: M. Ahmed, M. Douek
Meta‐analysis of the oncological safety of autologous fat transfer after breast cancer. BJS 2018; 105: 1082-1097.
Authors: T. K. Krastev, S. J. Schop, J. Hommes, A. A. Piatkowski, E. M. Heuts, R. R. W. J. van der Hulst et al.
Notes: Lipofilling ok
Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer‐specific survival.
Authors: S. E. Ward, P. D. Richards, J. L. Morgan, G. R. Holmes, J. W. Broggio, K. Collins et al.
Notes: Surgery should be first choice
Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction.
Authors: H. Adam, A. C. Docherty Skogh, Å. Edsander Nord, I. Schultz, J. Gahm, P. Hall et al.
Notes: DIEP is safe
Predictors of complications after direct‐to‐implant breast reconstruction with an acellular dermal matrix from a multicentre randomized clinical trial.
Authors: V. L. Negenborn, R. E. G. Dikmans, M. B. Bouman, H. A. H. Winters, J. W. R. Twisk, P. Q. Ruhé et al.
Notes: Not good for large breast
Population‐based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node‐positive invasive lobular carcinoma of the breast. BJS 2018; 105: 987-995.
Authors: E. Morrow, A. Lannigan, J. Doughty, J. Litherland, J. Mansell, S. Stallard et al.
Notes: Less sensitive in lobular carcinoma
Routine histopathological examination after female‐to‐male gender‐confirming mastectomy. BJS 2018; 105: 885-892.
Authors: S. M. J. Van Renterghem, J. Van Dorpe, S. J. Monstrey, J. Defreyne, K. E. Y. Claes, M. Praet et al.
Notes: The case for
Meta‐analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. BJS 2018; 105: 469-481.
Authors: A. Karakatsanis, M. K. Tasoulis, F. Wärnberg, G. Nilsson, F. MacNeill
Notes: Still unnecessary mastectomies
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non‐surgical management of triple‐negative breast cancer. BJS 2018; 105: 535-543.
Authors: R. F. D. van la Parra, A. B. Tadros, C. M. Checka, G. M. Rauch, A. Lucci, B. D. Smith et al.
Notes: Ductal carcinoma in situ and microcalcification important
Authors: Z. E. Winters, J. R. Benson